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ABSTRACT: Measures of the adipokine chemerin are elevated in multiple cardiovascular diseases, including hy-
pertension, but littlemechanisticworkhasbeendone to implicate chemerin asbeing causative in suchdiseases. The
chemerin knockout (KO) rat was created to test the hypothesis that removal of chemerin would reduce pressure in
thenormal andhypertensive state.Western analyses confirmed loss of chemerin in theplasmaand tissuesof theKO
vs.wild-type (WT) rats. Chemerin concentration in plasma and tissueswas lower inWT females than inWTmales,
as determined by Western analysis. Conscious male and female KO rats had modest differences in baseline mea-
sures vs. the WT that included systolic, diastolic, mean arterial and pulse pressures, and heart rate, all measured
telemetrically. The mineralocorticoid deoxycorticosterone acetate (DOCA) and salt water, combined with unin-
ephrectomy as a hypertensive stimulus, elevatedmean and systolic blood pressures of themaleKOhigher than the
male WT. By contrast, all pressures in the female KOwere lower than their WT throughout DOCA-salt treatment.
These results revealed an unexpected sex difference in chemerin expression and the ability of chemerin to modify
blood pressure in response to a hypertensive challenge.—Watts, S. W., Darios, E. S., Mullick, A. E., Garver, H.,
Saunders, T. L., Hughes, E. D., Filipiak,W. E., Zeidler,M.G.,McMullen, N., Sinal, C. J., Kumar, R. K., Ferland,D. J.,
Fink, G. D. The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hy-
pertension. FASEB J. 32, 6596–6614 (2018). www.fasebj.org
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Chemerin was originally described as a peptide found in
inflammatory fluid (1). It has since been described as an
adipokine (2–4) and has gained attention as a result of
findings of elevated blood levels in multiple human dis-
eases. These include obesity (5–9), overweight children
(10), metabolic syndrome (2, 11–16), rheumatoid arthritis
(17), type 2 diabetes (18–20), polycystic ovarian syndrome
(21–23), coronary artery disease (24), obstructive sleep
apnea (25), renal dysfunction with and without type 2
diabetes (26–28), acute ischemic stroke (29), nonalcoholic
fatty liver disease (30), atrial fibrillation (31), psoriasiswith
subclinical cardiac involvement (32), and preeclampsia
(33–35). The intent of this nonexhaustive list is to make
the point that the epidemiologic and clinical measures of
chemerin (36) are strong in implicating chemerin in dis-
ease, particularly those involving cardiovascular dys-
function.However, our understanding of themechanisms
bywhich chemerinparticipates in thesediseases, such that
chemerin could be identified as causal or participatory in
the disease—as opposed to being associative—is poor.
Presently, we focus on the endpoint of blood pressure as it
is regulated by chemerin.
Chemerin has prohypertensive actions in the vascula-
ture. First, the biologically active peptide chemerin-9 (37)
constricts isolated human and rat arteries (38, 39); the
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efficacyof chemerin-9 increases in arteries froma ratmade
deoxycorticosterone acetate (DOCA)-salt hypertensive or
in normal rats with the endothelial layer removed (38).
Chemerin-induced contraction is mediated by the Chem-
erin1 receptor (formerly known as ChemR23) (40, 41)
and uses signaling pathways well established as mediat-
ing smooth muscle contraction (42–44). Second, chemerin
reduces endothelium-dependent relaxation and aug-
ments arterial contraction to other agonists (43, 45). Third,
stimulation of the Chemerin1 receptor by the agonist
chemerin-9 amplifies electrical field-stimulated sympa-
thetic nerve-mediated arterial contraction (46). These 3
events would promote an elevation in blood pressure by
increasing total peripheral resistance. Recently, Kunimoto
et al. (47) showed that chronic chemerin infusion (.6 wk)
in the mouse elevates blood pressure. Importantly,
chemerin expression is observed in the perivascular adi-
pose tissue (PVAT), immediately adjacent to an artery, in
themedia ofwhich theChemerin1 receptor is expressed in
the rat and human (38, 48). Finally, independent groups
have confirmed that chemerin is a constrictor in human
arteries (38, 39). Thus, the components of the vasculature
are arranged in the human and rat in such a way that the
agonist chemerin (in PVAT) is expected to be prohy-
pertensive through stimulation of the medial Chemerin1
receptor. The vascular studies cited support this idea and
support the use of the rat as amodel to test the physiologic
importance of chemerin to blood pressure regulation.
Weaimed to study the contributionsmadeby chemerin
to blood pressure in two ways. First, we asked whether
chemerin played a role in normal blood pressure regula-
tion. Second, we wanted to determine whether the pro-
hypertensive actions of chemerin would be revealed in a
hypertensionmodel. Tomove these studies into thewhole
animal and perform experiments that permit more than
associative links to be made between chemerin and
blood pressure, we created the chemerin knockout (KO)
rat. This approach, rather than using a specific recep-
tor antagonist, was done to understand the totality of
chemerin’s contributions to the cardiovascular system. The
chemerin KO rat was created using clustered regularly
interspaced short palindromic repeats/CRISPR-associated
system (CRISPR/Cas) technology and single-guide RNAs
(sgRNAs) against the chemerin gene, retinoic acid receptor
responder protein 2 (Rarres2; also known as tazarotene-
induced gene 1 protein). Themineralocorticoid-dependent
hypertension model—the DOCA-salt rat—was used be-
cause chemerin-9-induced maximal contraction of arteries
isolated from the DOCA-salt rat was elevated compared
with arteries from sham normotensive rats (38). The hy-
pothesis tested, in both male and female rats, was that re-
moval of chemerin would reduce blood pressure under
normal conditions and in DOCA-salt hypertension.
MATERIALS AND METHODS
Construction of chemerin WT and KO rat
This original work was done at the Transgenic Animal Model
Facility at the University of Michigan. CRISPR/Cas9 tech-
nology (49, 50)was used to generate a geneticallymodified rat
strain with a chemerin (Rarres2) gene KO. Five sgRNA targets
were identified with the algorithm described byHsu et al. (51)
and cloned into plasmid pX330 (plasmid 42230; Addgene,
Cambridge, MA, USA; a kind gift of Feng Zhang, Mas-
sachusetts Institute of Technology, Cambridge, MA, USA), as
described in Ran et al. (52). Each circular pX330 plasmid was
coelectroporated into primary rat embryonic fibroblasts with
a PGKpuro plasmid (53). Genomic DNA was prepared from
the cells after transient selection with puromycin. A 599 bp
DNA fragment spanning the expected Cas9 cut site was PCR
amplified with forward primer 59-CCCCCAACCCCTTA-
ACTTAG-39 and reverse primer 59-GACTTGGGACATGG-
AGGAAA-39. Ampliconswere subjected toCEL 1 endonuclease
digestion, essentially as described (54). In brief, amplicons
were melted and annealed and then subjected to CEL 1 di-
gestion. The digests were analyzed by agarose gel electro-
phoresis. Gels were stained with SYBR Gold (S11494; Thermo
Fisher Scientific, Waltham, MA, USA) to achieve greater
sensitivity in the detection of insertion/deletion mutations
(indels) in the amplicons. The presence of indels produced by
nonhomologous-endjoining repair of Cas9-induced double-
strand breaks resulted in the presence of lower MW DNA
fragments following CEL 1 endonuclease digestion for the
sgRNA target. One sgRNA and protospacer adjacent motif
showed chromosome cleavage activity in exon 2. The active
guide target was 59-GTCCGCTGTGCCCAGCCATA-39 pro-
tospacer adjacent motif: GGG with a cut site in codon 11.
Rat zygote microinjection
Rat zygote microinjection was carried out as described (55).
Animals were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited facility
in accordance with the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, Bethesda, MD, USA).
Procedures were approved by the University of Michigan’s
Institutional Animal Care and Use Committee. pX330 plas-
mid DNA expressing the active sgRNAwas purified with an
Endotoxin-Free Kit (Qiagen, Germantown, MD, USA). DNA
concentration was adjusted to 5 ng/ml for pronuclear mi-
croinjection (56). Fertilized mouse eggs (30) were micro-
injected with purified DNA to detect embryo toxicity before
large-scale rat zygote microinjection. These mouse eggs
survived microinjection and developed to the blastocyst
stage in cell culture, indicating that the purified pX330 DNA
was nontoxic. Rat zygotes for microinjection were obtained
by mating superovulated Sprague-Dawley females with
males of the same strain [Crl:CD(SD), strain code 1; Charles
River Laboratory, Wilmington, MA, USA]. Four hundred
forty-nine rat zygotes were microinjected; 349 survived in-
jection and were transferred to pseudopregnant females.
Genomic DNA was isolated from tail-tip biopsies of 86 po-
tential founders that were born and analyzed for CRISPR/
Cas9-induced indels with a CEL 1 endonuclease. A total of 49
G0 rat pups (60%) were identified as carrying mutations in
Rarres2. Five G0 founder rats were identified for breeding to
obtain germline transmission of themutantRarres2gene. Cloning
and DNA sequencing (57) of 65 G1 pups showed that 3 G1 off-
spring (2 males and 1 female) were heterozygous for the same
mutation in the Rarres2 gene. The mutant allele had a 240 bp
deletion around the expected Cas 9 cut site. Nonhomologous
endjoining removed 181 bp from the 39 side of intron 1 and the
first 59 bp of exon 2, including the splice acceptor and the first 36
coding bases of Rarres2. One G1 male and G1 female were in-
terbred. Thirteen G2 pups from this first heterozygous breeding
were born, 7 of which were wild type (WT) and 6 of which were
heterozygous. The original founders and these pups were trans-
ferred to Michigan State University and regenotyped for confir-
mation using the PCR conditions described later. Heterozygous
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G2 pups were bred to result in the first G3 homozygousWT and
KO animals.
Validation of KO rat
Ear or tail tissue was taken for every rat before experimentation
and in some rats following experimentation to validate/confirm
the genotype of the rat. PCR was used with the following pa-
rameters: forward primer: 59-GACTTGGGACATGGAGGAAA-
39; reverseprimer:59-CCCCCAACCCCTTAACTTAG-39.GoTaq
Green (M7128; Promega, Madison, WI, USA) was used, accord-
ing to the manufacturer’s protocol on a real-time cycler. Cycling
conditionswere 13 95°C, 1min; 35 cycles of 95°C, 15 s, then 58°C
for 15 s, and then 72°C for 40 s; and 13 72°C, 4min and then 4°C
after. Expected WT product size is 600 bp, and the mutant allele
product is 360 bp, run on a standard agarose gel.
Breeding
Heterozygous pairs of animals continued to be bred, with
breeding pairs retired after 6 mo, and animals crossed outside of
brother-sister breedings. Ear punches from the male and female
KOwere sent back to theUniversity ofMichigan for validationof
the KO and determination of the damage in both alleles (see
Supplemental Fig. 2).Asanticipated, bothalleles lacked the splice
site and the first12 aaof exon2.Oncegenotyped,WTandKOrats
were implantedwithan IMI-500 transponderunder theneckskin
forunique identification.The transponderwas readby theBMDS
Smart probe (BioMedic Data Systems, Seaford, DE, USA). This
allowed us to house animals together in a social nature where
possible, while being confident in individual rat identity.
Animal use and husbandry
All animals were housed in temperature-controlled rooms and
given free access to foodandwater.Roomsweremaintainedon a
12-h light/dark cycle. All animals received enrichment in their
cages (shelter, tubes, Nylabones), and breeding/weaning fe-
males also hadnestingmaterials placed in their cage. Cageswere
checked daily. When pups were born, each pup was visually
checked for milk in its belly as a sign of successful feeding by its
mother (e.g., adequate maternal care). All animals were ran-
domized to the experiment in which they participated. Age-
matchedWT littermates were always used as controls.
Phenotyping and clinical chemistry
Animals were bled (under isoflurane anesthesia in 2% ox-
ygen, inhalation) through a tail-vein draw or as a terminal
draw through a ventricular puncture. Blood was placed in a
BD Vacutainer K2 EDTA tube (Becton Dickinson, Franklin
Lakes, NJ, USA) and immediately placed on ice. Blood
was spun at 2000 rpm for 20 min on a Sorvall Legend XTR
centrifuge (Thermo Fisher Scientific) at 4°C. Plasma was
separated from clotted blood components and taken for
protein measurement using a Bicinchoninic Assay Kit
(BCA1-1KT; MilliporeSigma, Burlington, MA, USA). These
samples were then used for either detection of plasma chemerin
or for clinical measures. From this point, the operator was blin-
ded to whether the sample came from a KO or WT rat. The
operator was not blinded to whether the sample came from a
male or female, as such information was required for setting up
separate gels or for grouping for clinical chemistry. Plasma
clinical values are listed in Table 1 and were measured on a
clinical analyzer (Olympus, Center Valley, PA, USA) following
the manufacturer’s instructions. T
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Western analyses
Plasma or tissue homogenates were used to validate KO at the
tissue level. All samples had 100mg total protein loaded per lane
on standard polyacrylamide gels (15%). Gel proteins were
transferred to PVDF-FL membrane using wet transfer. Li-Cor
Revert Kit (Lincoln,NE,USA)was used to stain total protein and
scanned on the 700 channel of a Li-Cor Odyssey CLx. The
membrane was then rehydrated in methanol, rinsed in water,
incubated in reversal solution for 5min, and then rinsed inwash
solution twice. All blots were then blocked in 4% chick egg ov-
albumin (A5378; MilliporeSigma) for 3 h on a rocker at 4°C.
Chemerin antibody [112520; Abcam, Cambridge, United King-
dom; Research Resource Identifier (RRID): AB_10864055], di-
luted to 1:1000 inblockingbuffer,was incubated for 48–72 hwith
constant rockingat 4°C.Blotswere then rinsedwithTris-buffered
saline + 0.1% Tween-20, 3 times for 10 min, followed by in-
cubation with Li-Cor IRDye secondary antibody (926-32210,
800CWgoat anti-mouse at 1:1000;RRID:AB_621842) for 1 hwith
rocking. Secondary solution was removed, and the blot was
washed 3 3 10 min with Tris-buffered saline + Tween and im-
aged on a Li-Cor Odyssey CLx in the 800 channel. A transferrin
antibody was used as a loading control for plasma (ab82411;
Abcam; RRID:AB_1659060),while Li-Cor total protein stainwas
used for other proteins.
Tango assay
Bioactive chemerin was measured using a rat Chemerin1 re-
ceptor in a cell-based reporter assay, as described in Parlee et al.
(58). Human embryonic kidney 293T cells, which constitutively
express a fusion protein composed of a tobacco etch virus
protease linked to human-arrestin2 and a transcriptional-
transactivator (tTA)-dependent luciferase reporter gene, were
transfected with a plasmid (Chemerin1-TL-tTA) that expresses
a fusion construct of Chemerin1 joined at its C terminus to a tTA
by a tobacco etch virus N1a protease cleavage site. Chemerin
binding to the Chemerin1-tTA fusion protein recruits the
arrestin-protease fusionconstruct to the receptor, resulting in tTA
cleavage, allowing tTa to pass into the nucleus, where it tran-
scribes the luciferase reporter gene. Concentration response
curves were conducted for rat recombinant chemerin and rat
plasma samples tested in a blinded fashion (e.g., no prior
knowledge of WT, KO, or male or female status). The control of
these same cells without the Chemerin1-tTA fusion protein was
run, and the values reported for each plasma sample were de-
rived by subtracting the value observed in the no-receptor sam-
ple from the receptor sample.
Proteome profiler adipokine array
An equivalent amount of total protein (1 mg) from plasma of a
WT and KO rat was incubated concurrently on rat-specific
adipokine arrays (ARY016; R&D Systems, Minneapolis, MN,
USA), according to the manufacturer’s protocol. IRDye 800CW
streptavidin secondary antibody (926-32230; Li-Cor; RRID: AB_
2722576) was used as the secondary antibody to develop the
array and analyzed on the Li-Cor Odyssey CLx in the 800
channel.
Isometric contraction
The thoracic aorta and superior mesenteric artery were dis-
sected and placed into physiologic salt solution [PSS; in mM:
NaCl 130, KCl 4.7, KH2PO4 1.18, MgSO4 × 7H2O 1.7, NaHCO3
14.8, dextrose 5.5, CaNa2 EDTA 0.03, CaCl2 1.6 (pH 7.2)].
Vesselswere guided onto awire in a silastic-filled Petri dish and
cleaned of PVAT under PSS. The endothelium was removed in
the thoracic aortic rings for the purpose ofmeasuringmaximum
chemerin-9-induced contraction, whereas the endothelium was
left intact in the superior mesenteric artery for measurement of
endothelial function.These twodifferentarterieswereused from
the same rat andexperimentsdone such that theWTandKOrats
were always paired.Wewere capable ofmounting 6 tissues in a
day, with rat aortic rings 2E from WT and KO and 2 rings of
superior mesenteric artery +E of WT and KO. This allowed for
direct comparisonsof the effects of life-long chemerin removal in
response to chemerin (aorta) and 2 important parameters of
vascular function, contraction to norepinephrine (NE), and en-
dothelial function (mesenteric artery). Cleaned vessels cut into
rings (;3 mm wide) for measurement of isometric contractile
force. Rings were mounted in warmed (37°C) and aerated (95%
O2, 5% CO2) tissue baths (30 ml PSS) on Grass isometric trans-
ducers (FT03; Grass Instruments, Quincy,MA,USA), connected
to an ADInstruments PowerLab (ADInstruments, Colorado
Springs, CO, USA). Tissues were placed under optimal resting
tension (thoracic aorta 4000 mg; superior mesenteric artery
1200 mg) and allowed to equilibrate for 1 h before an ini-
tial challenge with a maximal concentration of phenylephrine
(PE; 1025 M, P6126; MilliporeSigma). After this challenge, tis-
sues were washed until the tone returned to baseline. Tissues
were contracted with a half-maximal (1028 M) concentration
of PE and the endothelium-dependent relaxant acetylcholine
(ACh; 1026 M, A9101; MilliporeSigma) added to test for re-
moval (aorta) or intactness (mesenteric artery) of the endothelial
layer. Tissues were washed again multiple times until the tone
returned to baseline. For the aorta, cumulative concentration
response curves toChemerin-9 (0248;Genscript, Piscataway,NJ,
USA) were constructed, with additions made only after con-
traction plateauedwith an addition. For the superiormesenteric
artery, cumulative curves to NE (A7256; MilliporeSigma) or to
ACh (in a half-maximally PE-contracted tissue) were performed
randomly such that time was not a factor in the tissue response.
Telemetry implantation
Radiotelemeter transmitters (model TA11PA C40 or S10; Data
Sciences International, St. Paul, MN, USA), with attached cathe-
ters with pressure-sensing tips, were implanted subcutaneously
through a 1–1.5 cm incision in the left inguinal area, whereas rats
wereunder isofluraneanesthesia.Catheterswere introduced into
the left femoral artery, 3–5mmdistal to the level of the peritoneal
wall, and the tipwas advanced to the abdominal aorta. Ratswere
allowed3–4d to recover postoperatively, and then 4dof baseline
measurements were made. Mean arterial pressure, systolic
pressure, diastolic pressure, heart rate, and pulse pressure were
recorded throughout the duration of the study, both during this
baseline period and after DOCA-salt treatment (later). Measures
were recorded for 10 s every 10 min throughout the duration of
the study and are presented as a 24 h average, as collected by
Dataquest Art v.4.2 software (Data Sciences International).
DOCA-salt surgery and tissue procurement
All animals served as their own control. After baseline record-
ings, all animals underwent a uninephrectomy and implanta-
tionof aDOCA-impregnated silasticpellet at adoseof 200mg/kg,
s.c. At the same time, animalswere placed on drinkingwaterwith
1.0%NaCl and 0.2% KCl. Animals were on this regimen for 4 wk
and then euthanized. Under isoflurane anesthesia, blood samples
were taken for plasma, and tissues were removed for weight, for
preparation of a histologic sample, or for Western analyses.
CHEMERIN KO RAT AND BLOOD PRESSURE 6599
Data presentation
Data are reported as means 6 SEM for the number of indi-
vidual animals, indicated in parentheses with most graphs
in scatterplot. In some instances, a box and whiskers form is
used, reporting median and quartiles. For Western analy-
ses, Li-Cor Image Studio v.5.2.5 (RRID: SCR_015795) was
used for visualization of the total protein stain on the blot
and visualization of chemerin. Images shownwere modified
in brightness/contrast only as a whole. Tango results were
determined by a standard curve run in every experiment,
and samples were run in duplicate. Adipokine arrays were
visualized on the Li-Cor CLx instrument, and pairedWT and
KOwere always scanned together such that comparisons can
be made between the 2. The Li-Cor CLx Image Studio pro-
gram was used to quantify the spots on the array. Contrac-
tility data are reported as a percentage of PE contraction.
Potency values [2log EC50 value (M)] were calculatedwithin
Graph Pad Prism 7.0 (GraphPad Software, La Jolla CA, USA;
RRID: SCR_015807). If maximum values were not achieved,
then the potency values reported are estimated, and true
values are equal to or greater than these estimated values.
Telemetry-derived values (all pressures, heart rate, activity,
temperature) were captured by the Dataquest ART program
of Data Sciences International. Imaging of histologic samples
was performed on a Nikon TE2000 inverted microscope
(Tokyo, Japan) with the Cell Tools program (Molecular Ma-
chines & Industries, Zurich, Switzerland).
Statistics
When comparing 2 groups, the appropriate paired or unpaired,
1- or 2-tailed Student’s t test was used when variances were
equal.When comparing 3 ormore groups at the same timepoint,
a 1-wayANOVAwith Tukey’s post hocwas used to compare the
groups among one another, as long as variances were equal, as
validated by Bartlett’s test. When comparing 3 or more groups
over time, a repeated-measures ANOVA with Tukey’s post hoc
was used. For blood pressures, times were divided into week-
long segments for statistical comparisons. When variances were
unequal, a Kruskal-Wallis test, followedbyDunn’s testwas used
to determine statistical differences among 3 or more groups.
RESULTS
Chemerin gene was successfully mutated
Supplemental Fig. S1 shows the design for mutation of
exon 2 of the Rarres2 gene (Supplemental Fig. S1A) and
the DNA mutations (Supplement Fig. S1B; mutant vs.
WT) in the first pups born after sgRNA administration to
Sprague-Dawley zygotes from Charles River Laborato-
ries. The male and female heterozygotes born from these
original mutated rats were used as breeding pairs for
creating theWT and KO rats that were used in this study.
Validation of homozygous mutation, placed in exon 2 of
the Rarres2 gene, was performed at the University of
Michigan in a blinded fashion, an example of which is
shown in Supplemental Fig. S2.
Circulating and tissue chemerin was
abolished in the KO rat
In the original second filial generation of rats, Rarres2
was successfully mutated homozygously, as verified
through genotyping (Fig. 1A, upper). Chemerin protein
was abolished in the plasma in those same animals with
a KO genotype when compared with those with a WT
genotype (Fig. 1A, lower). In other cohorts (12–14 wk
olds), plasma, liver, and retroperitoneal (RP) fat were
taken from littermatemales and females to test whether
the Rarres2 mutation reduced chemerin protein syn-
thesis in tissues. Plasma chemerin of the KO vs.WTwas
abolished (Fig. 1B) in both sexes. Unexpectedly, plasma
chemerin was significantly lower in WT females than
WTmales (Fig. 1B, left and right). A TangoGPCR assay,
designed to detect active chemerin isoforms (58) (stan-
dard curve in Fig. 1C, left), was not able to detect a
significantly higher level of active chemerin in the
male WT vs. KO, although the male WT values were
quantitatively higher (Fig. 1C, right). No differences
were observed between female WT and KO samples.
Reflective of plasmameasures, chemerinwas abolished
in the liver and RP fat of the male and female KO when
compared with their respective WT (Fig. 2) and was
significantly lower in content in the female vs.male liver
(Fig. 2A). A total protein stain of the membrane before
development of the blot with antibody was performed
as a loading control and is shown for each experiment,
as depicted in Figs. 1 and 2.
Chemerin KO rat appears grossly normal
vs. WT: growth, tissue weights, and
clinical values
The first litters of KO andWTbornwere allowed to age
to 20 wk to observe growth (Fig. 3A, left); this ulti-
mately included only 1 female KO rat. At 20 wk of age,
there was no statistical difference in the absolute body
weight, total fat content, kidney, liver, spleen, or heart
weights in the male KO vs. WT (reported as absolute
values or as a percentage of body weight; Fig. 3A,
right). Female rats were significantly smaller than
males when age matched. No gross abnormalities in
perigonadal (PG) fat, a source of chemerin, of the KO
malewere noted, althoughKOadipocytes tended to be
bigger than WT (Fig. 3B). Gross histology of the liver
and skin, 2 sites in addition to fat where chemerin is
made, revealed no substantial differences in cellular
organization or tissue structure (data not shown). In
later cohorts of animals, the Adipokine Proteome
Profile Arrays revealed no complete loss of any of the
27 adipokines tested on this array in the KO vs. WT
(data not shown). Clinical panels on plasma frommale
and female KO and WT rats are shown in Table 1.
Values for alanine aminotransferase, total bilirubin,
total cholesterol, creatinine, glucose, triglycerides,
blood urea nitrogen (BUN), and nonesterified fatty
acids (NEFAs) were not different between male and
female KO rats when compared with their respective
WT controls. For albumin, values in the females were
higher when compared with those from the male. For
aspartate aminotransferase (AST), the male KO was
significantly lower than male WT. Finally, ketone
levels in the femaleWTwere significantly greater than
the male WT.
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Arteries from the KO rat show enhanced
contractility selectively to Chemerin-9 vs.
the WT
Arteries from littermate male and female WT and
KO rats (12–14 wk) were used to investigate basic ar-
terial function, including contraction to the adrenergic
agonist NE and endothelium-dependent relaxation to
ACh, as well as contraction to the Chemerin-1 receptor
agonist Chemerin-9. Table 2 reports the potencies
[2log EC50 values (M)] and maximums that define the
pharmacological curves shown in Fig. 4. In males (Fig.
4A) and females (Fig. 4B), Chemerin-9–induced maxi-
mum contraction was greater in the KO vs. WT (Fig. 4,
left). Moreover, Chemerin-9–induced maximum con-
traction in aorta from the male was greater than their
genotype-matched female (percent PE contraction; WT
male: 71.9 6 10.6; female: 40.7 6 7.6, P , 0.05). The
Figure 1. A) Validation of WT,
heterozygous (Het), or KO sta-
tus using PCR (upper) and
Western analyses (lower) of
plasma in 10 different animals
(each one per lane). Transfer-
rin was used as a loading control
for protein. DNA and protein
samples are from the same
animal, as marked by WT, Het,
or KO rats. Plus sign indicates
liver homogenates from a nor-
mal male Sprague-Dawley rat.
Representative of over 200 rats.
B) Comparison of chemerin in
male and female rats from
plasma (left). +, normal Sprague-
Dawley male (from outside of
colony) liver homogenate. Arrow
points to chemerin. Total protein
stain on membranes was done
before blocking and adding the
primary antibody against chem-
erin. Chemerin signal was nor-
malized to total protein for each
respective lane in the graph
(right), where horizontal bars
are means 6 SEM for number of
animals in parentheses, sur-
rounded by individual plotted
values. C) Standard curve for
human (h)chemerin in the
Tango rat (r)Chemerin-1 assay
(left) and in plasma from WT
and KO male and female rats
(right), as measured as receptor-
dependent signal. Asterisk de-
notes signiﬁcantly different vs.
same sex WT; dagger indicates
comparison to different male WT,
as determined by ANOVA, fol-
lowed by Tukey’s post hoc test.
RLU, relative light units.
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potency of Chemerin-9 was elevated in the KO vs.
the WT, male and female, although potencies were
estimated, given that a maximum was not formally
achieved. These findings contrasted with no change in
potency or maximum-induced contraction caused by
NE in between the male WT and KO, the female WT
and KO, or between genotype-matched male and fe-
male (Fig. 4, middle). Likewise, maximum PE contrac-
tion (reported in legend) was not different, using these
same comparisons. Finally, there was no change in
the potency or efficacy of ACh-induced relaxation in
PE-contracted arteries when comparing KO and WT
within a sex (Fig. 4, right). Superior mesenteric rings
from the males (KO and WT) relaxed completely to
ACh, whereas ;16–19% of PE-induced contraction
remained in the female. This difference was not modi-
fied by removal of chemerin.
We investigated thepossibility of anadaptive change in
chemerin receptor expression by measuring mRNA ex-
pression of Chemerin-1, Chemerin-2, and CCRL2, all re-
ceptors for chemerin, in a tissue saved from the WT and
KO rats used in the contractility experiments—the brown
fat pad. Consistent with a loss of chemerin, Chemerin1
mRNAandChemerin-2mRNAwere elevated in themale
KO vs.WTbut not the female. Expression ofCCRL2 in this
tissuewas lower than theother 2 receptors, anddifferences
between the WT and KO could not be detected (Supple-
mental Fig. S3).
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Figure 2. Comparison of chemerin in liver (A) and RP fat (B) from male (left blots) and female (right blots) rats. Plus sign
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Figure 3. A) Growth curves for male and female and male tissue weights (absolute, percentage body weight; right) of some of the
ﬁrst WT and KO progeny born. Horizontal bars represent means 6 SEM, surrounded by scattered values for the number of
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grow to 20 wk. Insufﬁcient female KO were born in these litters to include them in these measures. Bars represent means 6 SEM
for the number of animals in parentheses. Original scale bars, 50 mm. Animals included in this graph are all littermates.
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Basal cardiovascular parameters of chemerin
WT and KO rats are not different
In another 3 separate cohorts of animals (bornat 3 separate
times, months apart; aged 10–14 wk at beginning of ex-
periment), radiotelemeters were implanted for measure-
ment of basal blood pressures (mean, systolic, diastolic,
and pulse) and heart rate. Measures from 4 days of these
parameters, gathered in the conscious state, and 5 d after
telemeter implantation are shown in Fig. 5. Supplemen-
tal Fig. S4 demonstrates the circadian rhythm of these
animals during the time period over which the 4 d of
control measures were taken, validating that they were in
normal rhythm during baseline measurements.
Pressures
Loss of chemerin did not change mean arterial blood pres-
sure when comparing WT and KO within a sex (Fig. 5A).
However, male KO rats had a higher systolic (Fig. 5B) and
lower (Fig. 5C) diastolic pressure than their WT controls.
This was reflected in the significantly lower pulse pres-
sure in male WT compared with male KO (Fig. 5D). By
contrast, female pressures—mean, systolic, diastolic, or
TABLE 2. Potency and efﬁcacy of Chemerin-9, NE, and ACh in aortic rings from male and female WT and KO rats
Compound
Male WT Male KO Female WT Female KO
2Log EC50 (M) Max 2Log EC50 (M) Max 2Log EC50 (M) Max 2Log EC50 (M) Max
Chemerin 6.76 6 0.15 71.9 6 10.6 7.11 6 0.06* 113.5 6 3.6* 6.16 6 0.18 40.7 6 7.6† 6.79 6 0.18* 59.5 6 7.8*,†
NE 7.65 6 0.16 143.1 6 2.3 7.67 6 0.16 170.1 6 27.0 8.32 6 0.16 159.9 6 5.4 8.57 6 0.19 164.6 6 34.4
ACh 8.02 6 0.04 0 6 0 7.83 6 0.04 0 6 0 7.66 6 0.12 18.91 6 5.2† 7.34 6 0.04 16.0 6 1.00†
Points are means6 SEM for number of animals indicated in Fig. 4. Max, maximum effect achieved, reported as a percentage of the maximum
PE (Chemerin-9, NE) or as a half-maximal PE contraction remaining (ACh). *P , 0.05 between same sex value vs. WT. †P , 0.05 between
different sexes of same genotype with female values marked.
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Figure 4. Arterial responses to Chemerin-9 (left), NE (middle), and ACh (against a half-maximal PE contraction; right) in rings
of thoracic aorta and superior mesenteric arteries from male (A) and female (B) WT and KO rats. Points are means6 SEM for the
number of animals in parentheses. Asterisk denotes signiﬁcant differences (P , 0.05) by a 2-way ANOVA with Bonferroni’s
correction between WT and KO. Contraction to PE (y axis): male aorta: WT = 1987 6 107 mg, KO = 1677 6 81 mg (P . 0.05);
male superior mesenteric artery: WT = 11506 38 mg, KO = 9446 29 mg (P. 0.05); female aorta: WT = 13816 70, KO = 16036
66 mg (P . 0.05); female superior mesenteric artery: WT = 804 6 26 mg, KO = 920 6 45 mg (P . 0.05). Statistical analysis for PE
contraction was done using an unpaired Student’s t test between the KO and WT values.
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Figure 5. Mean arterial pressure (MAP; A), systolic blood pressure (SBP; B), diastolic blood pressure (DBP; C), pulse pressure
(PP; D), and heart rate (HR; E) in WT and KO male and female rats (number indicated in parentheses) over 4 control days.
Scatterplot values for the number of animals in parentheses around horizontal bars that are means. Repeated-measures 1-way
ANOVA was performed, followed by Tukey’s post hoc. Asterisk denotes statistically signiﬁcant (P , 0.05) differences between WT
and KO within same sex; dagger represents rats within same genotype but different sex; double asterisks signify between different
sex and different genotype.
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pulse—were not changed by loss of a functional chem-
erin gene. The circadian rhythm of mean arterial blood
pressure for a subset of animals over the course of 4dwas
normal (data not shown).
Heart rate
Asexpected,heart rate in the femaleswashigher thanmales
(Fig. 5E). Male WT had modestly higher heart rates than
male KO rats during this control period. Such a difference
was not observed between the female WT and KO rat.
Female but not male KO rats show reduction
in hypertension developed to DOCA-salt
The same animals in which basal parameters were mea-
sured all underwent a uninephrectomy and were given a
DOCA-impregnated pellet (200 mg/kg) and placed on
drinking water that contained 1% NaCl + 0.2% KCl. An-
imals were tracked for measurement of pressures and
heart rateover the standardDOCA-salt treatmentof 4wk.
Results are shown in Fig. 6 with DOCA-salt treatment
initiated at the dotted vertical lines. Repeated-measures
ANOVA for each variable was performed on all 4 groups
over time. Statistical results are shown only for the ge-
notype difference within a sex, and values for male and
female are graphed separately for clarity.
Pressures
Males responded toDOCA-saltwith the expectedelevation
in blood pressure. Contrary to our hypothesis, themaleKO
had a larger increase in mean and systolic blood pressure
than their WT controls (Fig. 6, left). Diastolic pressure was
variable (Fig. 6C, left) over time, such that the WT and KO
were not significantly different. Pulse pressure remained
elevated in the male KO DOCA vs. the male WT DOCA.
Females had a more modest elevation in blood pressure
(;7–8mmHgless) comparedwith themale’s in response to
DOCA-salt. Furthermore, in contrast to males, the increase
inmeanandsystolicanddiastolicbloodpressurewas lower
in the female chemerin KO vs. its littermate WT controls in
response to DOCA-salt (Fig. 6, right).
Heart rate
Heart rate in the male KO DOCA rat was lower than the
maleWTDOCA rat (Fig. 6E), whereas 2 groups of female
rats given DOCA-salt continued to be statistically similar
(Fig. 6E). Female heart rate remained higher than that of
their male littermates.
Body weights, tissues masses, and chemerin
expression at end of DOCA-salt
At the end of DOCA-salt treatment, tissues were re-
moved for measurement of body weight, fat weights,
and weights of end organs affected in hypertension
(kidney, liver, spleen, and heart). In Fig. 7A, left, abso-
lute weights were compared. An elevation in the
amount of RP fat and a tendency for PG fat to be ele-
vated in the male KO DOCA compared with WT
resulted in a gross measure of body fat (RP + PG) being
statistically greater in the male DOCA KO vs. WT but
not in the female. No such genotype-driven changes
were observed in the females. The elevation in total fat
in themaleDOCAKO vs.WTremained truewhen these
data were graphed as a percentage of body weight
(Fig. 7A, right). When comparing WT and KO within
each sex, there were no significant reductions in the
weights of the kidney, heart (Fig. 7A), or arterial medial
thickness/lumen ratio (data not shown), all of which
are target organs/tissue of hypertension. Importantly,
DOCA-salt itself did not abolish chemerin plasma ex-
pression (chemerin densitometry/total protein as ar-
bitrary densitometry units: male WT = 0.085 6 0.008;
male WT DOCA = 0.080 6 0.007; female WT = 0.044 6
0.005; femaleWTDOCA= 0.0586 0.019; P. 0.05when
comparing same-sex groups by 2-tailed t test). Figure 7B
shows, for a subgroup, that those animals studied in
radiotelemetry in Figs. 5 and 6 showed the appropriate
presence or absence of plasma chemerin in the WT and
KO, respectively.
DISCUSSION
The work presented in this manuscript is the first to de-
scribe a total bodyKOof the adipokine chemerin in the rat.
We created this animal to test how chemerin is involved in
blood pressure regulation.We hypothesized that removal
of the chemerin gene/proteinwould reduce normal blood
pressure and would attenuate the development hyper-
tension. Our data, as collected in Table 3, falsify this hy-
pothesis for themalebutare consistentwith thehypothesis
for the female.
Confidence in the KO rat
Confidence in KO of chemerin was supported by con-
sistent and repeatable genotyping, the observation that
phenotyping was consistent with genotyping, and a spe-
cific and expected upregulation of Chemerin-9-induced
contraction of arteries isolated from aKO vs.WT rat (male
and female). Enhanced contraction could be because of
upregulated Chemerin-1 receptor expression. At least in
the male brown fat pad, Chemerin-1 and Chemerin-2
mRNAwas elevated, consistentwith this idea. The lack of
elevation in the female with chemerin KO is interesting
and needs further exploration.
Westerns were used to phenotype samples, as no
commercially available ELISA kits reliably measure rat
chemerin. The Tango assay was an additional measure of
chemerin, one that detects active forms of chemerin (58).
Several limitations of this assay are important to mention.
First, in performing this assay for the first time in rat
plasma, we discovered that circulating rat chemerin, at
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least in nondiseased rats, is close to the detection level of
the assay. The lower limit of detection with rat serum/
plasma is;1 nM, and this is where the samples from the
females measure, making it difficult to demonstrate
a statistical difference. This assay typically has a large
signal/noise ratio and dynamic range but is subject to a
low background signal with biologic samples. This can
be corrected, to some extent, with nonreceptor controls,
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Time (days) Time (days)
Time (days) Time (days)
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Time (days) Time (days)
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Figure 6. Mean arterial pressure (A), systolic blood pressure (B), diastolic blood pressure (C), pulse pressure (D) and heart rate
(E) in WT and KO male (left) and female (right) rats given DOCA, salt water, and uninephrectomy at the dashed vertical lines
on d 8/9. Points are means 6 SEM for the number of animals in parentheses. Repeated-measures 1-way ANOVA was performed,
followed by Tukey’s post hoc on all 4 groups and only within-sex differences are shown in the graphs, grouped separately for
clarity. Asterisk denotes statistically signiﬁcant (P , 0.05) differences between WT and KO overall; dagger indicates difference as
determined within week-to-week comparison for simplicity.
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whichwere run, and this correctionhas thegreatest impact
on sampleswith chemerin bioactivity, at or near the lower
limit of detection, exactly the spot where our samples are.
Additionally, this assay measures activity relative to a
single-most active form of chemerin (Chemerin-157), and
biologic samples are likely to contain multiple forms of
chemerin protein. As such, the chemerin measured in this
assay is a fraction of what would be observed in the
Westerns. Finally, as the Tango assay relies on detection of
a single mode of receptor signaling through b-arrestin
recruitment, this signal may be dampened by forms of
chemerin that exhibit biased agonism and do not
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Figure 7. A) Endpoint body and tissue weights as absolute measures (left) or as a percentage body weight (right) in WT and KO
male and female rats given DOCA, salt water, and uninephrectomy for 4 wk. This box and whisker plot used the Tukey method,
where the center line is the median, and the whiskers only extend to the farthest point within 1.53 the interquartile range from
the edge of the box (box edges are always 25th and 75th percentiles). Points outside box are outliers. Asterisk denotes statistically
signiﬁcant (P , 0.05) differences between same sex WT. Dagger indicates between genders, as performed by 1-way ANOVA with
Tukey’s post hoc correction. B) Comparison of plasma chemerin in male (left side of blots) and female (right side of blots) rats
after 4 wk of DOCA-salt. Arrow points to chemerin. Plus sign indicates normal Sprague Dawley male (from outside of colony)
liver homogenate. Total protein stains on membranes were done before blocking and adding the primary antibody against
chemerin. Chemerin signal was normalized to total protein for each respective lane in the graph (right), where vertical bars are
means 6 SEM with scattered points for number of animals in parentheses. Asterisk denotes statistically signiﬁcant (P , 0.05)
difference between same-sex WT.
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effectively promote b-arrestin recruitment but preferen-
tially signal through other modes. This is an area just be-
ginning to be investigated. Overall, the approach of using
the Tango assay was useful in understanding its limita-
tions and providing at least a partial confirmatory mea-
sure that the KO (male) lacked bioactive chemerin and
that males have higher levels of plasma chemerin than do
females.
Chemerin KO rat is similar to the chemerin
KO mouse
Creation of a rat chemerin KO was important because
of the reliance of the hypertension field on the rat as a
model.We have somethingwithwhich to compare this
new animal, as the chemerin KOmouse was created in
2011 (59). Like the chemerin KO mouse, KO rats were
grossly normal, females weighed less than males, and
the KO gained weight with aging, similar to their re-
spective WT mouse. Likewise, plasma levels of cho-
lesterol and triglycerides were not modified between
KOandWT.Our studies also agree in thatNEFAswere
lower in the KO (female) vs. the WT. Whereas a re-
duction in NEFA in the KO vs.WTmice was observed,
it is unclear if this was observed in both sexes. Their
goals for removing chemerin in the mouse were dif-
ferent from ours, with their focus understanding the
glucose regulation. Their KO mice were glucose in-
tolerant compared with the WT. Whereas we did not
perform a glucose challenge, it is notable that the
resting glucose and triglycerides levels of all rats—KO
and WT, male and female—were higher than is re-
ported for normal male and female Sprague-Dawley
rats of a similar age (60). Our animals were not denied
access to food before taking their blood, and this likely
is the source of the elevated glucose and triglycerides.
AST (normal = 72–116 IU/L for male/female) and
BUN (10–17 mg/dl for male/female) were elevated
above normal in our rats compared with normal
Sprague-Dawley rats (60). There was, however, a re-
duction (normal) AST in the male KO vs. WT, and the
female KO AST was not different from WT. The same
was true for BUN. It is thus unlikely that removal of
chemerin causes general liver or kidney damage,
which is important to know with the consideration of
blood pressure regulation. Overall, there were more
similarities than differences between the chemerin KO
mouse and the chemerin KO rat.
Chemerin regulates blood pressure
differently in the male and female rat
Weneither expected to find that chemerin in the female
plasma and tissues would be lower than males nor do
we understand why this would be so. There has been
no direct comparison of chemerin in sexes, such as we
report here in the rat. This sex difference was observed
in all the cohorts of animals we tested, supporting the
reproducibility of this finding. A possible explanation
is that at least in the DOCA females, the fat depots, as
one source of chemerin, were a modestly smaller per-
centage of total body weight when compared with the
males. Interestingly, chemerin was modestly less po-
tent and significantly less efficacious in causing con-
traction of the isolated aorta from the female vs. the
male rat. This was also unexpected, given the lower
chemerin levels observed in the female vs. the male,
where one might expect a greater magnitude of con-
traction in the female vessels that are exposed endoge-
nously to a lower concentration of chemerin. This raises
the idea of sex differences in chemerin receptor expres-
sion in the vasculature, as well as consideration for what
long-term removal of chemerin does to receptor function.
These animals were born without chemerin, an approach
that is necessarily different in potential outcomes than
acute removal of chemerin.These ideaswill be explored in
future studies.
Even with these differences in chemerin expres-
sion, loss of chemerin did not modify basal mean ar-
terial blood pressure in either sex. The systolic and
diastolic blood pressures of the male KO were sig-
nificantly raised and lowered vs. theWT, respectively,
such that mean arterial pressures were not modified,
but pulse pressure was significantly elevated in the
KO; thesemeasures were unchanged in the female KO
vs.WT. An unexpected finding was reduction of heart
rate in the male KO vs. WT. There is no support for
chemerin directly affecting heart rate, but a few
studies investigate the interaction of chemerin and
the heart. Specifically, peptidase inhibitor 16 is a
regulator of chemerin processing in the myocardium
(61), serum chemerin concentration is associated with
atrial fibrillation and remodeling and dilated cardio-
myopathy with heart failure (31, 62), chemerin in-
duces apoptosis in murine cardiomyocytes (63), and
the chemerin gene is present in baboon and chim-
panzee hearts (64). Investigation into the potential for
chemerin-mediated changes in cardiac function has
merit.
Upon observing no differences in basal cardiovascular
parameters,wemoved to test theanimalswithachallenge.
We used an approach that took the greatest care in not
relying on sets of particular parents for WT and KO prog-
eny, not selecting the time of year in which the experi-
ment isdone,andbeingable toshowthatwecanreproduce
our findings in-house. Our use of the DOCA-salt model in
TABLE 3. Comparison of the general outcome of the KO vs. WT
during DOCA-salt hypertension
Parameter Male Female
MAP ↑ ↓
SBP ↑ ↓
DBP — ↓
PP ↑ —
HR ↓ —
Activity ↓ —
Body fat ↑ —
↑, increase; ↓, decrease; —, no change; DBP, diastolic blood
pressure; HR, heart rate; MAP, mean arterial pressure; SBP, systolic
blood pressure.
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the males and females was consistent with the published
finding that males typically achieve a higher magnitude of
blood pressure to DOCA-salt than the WT females (by
;7–8 mmHg) (65–70). Contrary to our hypothesis, re-
moval of chemerin elevated in the male but reduced in the
female themagnitudeof bloodpressure elevationachieved
with DOCA-salt. These data suggest that chemerin could
be anti-hypertensive in the male and pro-hypertensive in
the female. We did not investigate arterial contractility
(response to Chemerin-9, NE, andACh) in theDOCA rats,
and this would be interesting to do from the perspective of
knowing whether the male exhibited vascular hyper-
reactivity, whereas the female did not.
Sex differences in chemerin’s biologic actions have
not been investigated. The possibility that chemerin could
act in such opposing manners is supported by a litera-
ture that poses chemerin as being both inflammatory and
anti-inflammatory. Generally, studies support chem-
erin being prohypertensive, proinflammatory, and
propathogenic; these studies are the premise for the
original hypothesis of this work (5, 9, 71–77). By con-
trast, chemerin has been described as exerting anti-
inflammatory actions (78–81). For example, Cash et al.
(82) report that a synthetic, chemerin-derived peptide,
Chemerin-15, suppressed inflammation, as mediated
by the macrophage. Likewise, chemerin suppressed
murine allergic asthma (83) in the mouse and exerted
anti-inflammatory roles in human vascular endothe-
lial cells (81). The Chemerin-1 receptor mediated both
proinflammatory and anti-inflammatory actions in
diesel exhaust particulate-induced acute lung inflam-
mation in the mouse (84) and reduced lung inflam-
mation in amousemodel of acute viral pneumonia (85).
Others, though, have not found Chemerin-15 to be ef-
fective in ameliorating inflammatory disease (non-
alcoholic steatohepatitis) (86) or for causing direct
arterial relaxation (38). The complexity of the biologic
effects of chemerin is just beginning to be unraveled.
A possibility is that loss of chemerin unmasks
a difference in response of males and females to
other endogenous Chemerin-1 receptor agonists, such as
resolvin E1, a proposed activator of the Chemerin-1 re-
ceptor that provides resolution to inflammation (87).
For this to be true, resolvin E1 levels would have to be
higher in the females than the males, and these data are
not available in the rat or human. This, though, assumes
that it is only actions mediated by the Chemerin-1 recep-
tor that would be influenced by chemerin removal. Two
other receptors for chemerin exist: Chemerin-2 (for-
merly G protein-coupled receptor 1) and CCRL2 (73, 88,
89). Chemerin-2 can mediate biologic signals activated
by chemerin, whereas CCRL2 appears to be more of a
chaperone of chemerin. Chemerin-1 and Chemerin-2
mRNA levels were higher in themale KO vs.WT (brown
fat pad), suggesting that there are adaptations to loss of
chemerin. It will be our job to understand whether this
occurs throughout the body, including the vasculature,
and why this does not occur in the female. It stands to
reason that this difference in adaption could be why
males and females are different; other receptors and
agonists come to “rescue” the lack of chemerin in the
male but not the female. We cannot exclude that car-
diovascular processes mediated by either of these re-
ceptors or that the combination of all 3 are what
mediates, in the chemerin KO, the rise in arterial pres-
sure in males but falls in the females when given
DOCA-salt. One might expect that the male KO, and
less so the female KO, would be protected from hy-
pertension because of loss of the more highly expressed
chemerin. How chemerin functions at different sites
that control blood pressure, as well as interacts with
these different receptors, is somethingwe simply do not
know.We could not test some of these ideas, as specific
agonists/antagonists for Chemerin-2 and CCRL2 do
not exist. Likewise, we have not been able to use the
Chemerin-1 receptor antagonist CCX832 (38) in in vivo
experiments. It would be ideal to have an antagonist at
each chemerin receptor to, in an acute manner, un-
derstand the involvement of each chemerin receptor in
the regulation of blood pressure. Chemerin removal
could also cause changes in the male and female com-
plement of active immune cells, creating functional
differences between the sexes, such that final blood
pressures are modified. This is reasonable to consider
given the well-known actions of chemerin on immune
cell movement and function (1, 5, 37, 71) and the role of
immune cells, such as the macrophage in DOCA-salt
hypertension (90).
We have also studied only one model of experi-
mental hypertension. The DOCA-salt model was
used with purpose. Arteries isolated from the DOCA-
salt rat showed a profoundly increased contraction to
chemerin-9 when compared with arteries from sham
rats (38). This model is also known to depend on ac-
tivation of the sympathetic nervous system, a system
that chemerin amplified at the level of the arterial
neuroeffector junction (46). We hypothesized that we
would have the best chance of observing an effect on
blood pressure in the DOCA-salt model. Interest-
ingly, the DOCA-salt model showed a significant
loss in fat (;50%) compared with animals that are
close in age (compare Fig. 3B with 7B). As such, the
contributions of chemerin could have been under-
estimated by using a model that has loss of fat, 1
source of chemerin.
Is chemerin expression different in male and
female humans?
Are these findings meaningful to the human? The litera-
ture is considerably diverse about sex differences in
chemerin expression. Some literature supports differ-
ent chemerin levels in the female vs.male and different
responses in a pathologic state, although caution must
be taken, as chemerin was measured from different
body sources. For example, nocturnal serum chemerin
levels were higher in the obese female vs. normal
weight controls but not in males (91). Likewise, chem-
erin mRNA expression in subcutaneous fat was sig-
nificantly higher in women vs. men (92), but plasma
levelswere not different. A similar finding of higher s.c.
6610 Vol. 32 December 2018 WATTS ET AL.The FASEB Journal x www.fasebj.org
chemerin mRNA expression in female vs. male (nor-
mal) was observed by Martı´nez-Garcı´a et al. (93). This
raises the question of whether and how subcutane-
ous fat contributes to circulating chemerin levels.
Schmid et al. (94) demonstrated a significantly higher
basal chemerin serum concentration in the female vs.
the male in unfed, healthy volunteers. By contrast to
these reports that females have higher plasma levels or
subcutaneous mRNA of chemerin than males, Luque-
Ramı´rez et al. (95) found no difference in male vs. fe-
male. In a control group from a Japanese population
diagnosed with metabolic syndrome or type 2 diabe-
tes mellitus, chemerin levels in control males were
higher than females (96). In our model, chemerin levels
in the plasma in multiple cohorts were lower in the
female vs. themaleWT rats. The diversity in outcome of
this collective literature points to the importance of
recognizing the source of chemerin and the potential
that local actions of chemerin may bemore biologically
important than that reflected by plasma measures.
CONCLUSIONS
Creation of the chemerin KO rat by CRISPR/Cas9
technology revealed an unexpected sex difference in the
ability of chemerin to modify blood pressure during
challenge with a hypertensive stimulus of mineralo-
corticoid and salt. These intriguing data elevate the
importance of studying chemerin in blood pressure
regulation with an understanding that the chemerin–
chemerin receptor axis responds to absence of chemerin
somewhat differently in the male and female rat. Like-
wise, the finding of a significantly different level of
chemerin in the female vs.male begs the question as to
why this is so, whether this occurs at other levels of the
chemerin–chemerin receptor axis, and whether this
could be confirmed in independent labs in the human.
Such a finding would elevate chemerin and their re-
ceptors as potential biologic targets that may be sex
dependent.
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